Xiaoju Li Selected Research

T0901317

1/2021	Targeting macrophage liver X receptors by hydrogel-encapsulated T0901317 reduces atherosclerosis without effect on hepatic lipogenesis.
1/2020	Combination of MEK1/2 inhibitor and LXR ligand synergistically inhibit atherosclerosis in LDLR deficient mice.
12/2018	Activation of liver X receptor plays a central role in antiviral actions of 25-hydroxycholesterol.
1/2016	Activation of liver X receptor inhibits the development of pulmonary carcinomas induced by 3-methylcholanthrene and butylated hydroxytoluene in BALB/c mice.
4/2015	Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
4/2014	Identification of interferon-γ as a new molecular target of liver X receptor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiaoju Li Research Topics

Disease

24	Atherosclerosis 01/2021 - 06/2012
16	Neoplasms (Cancer) 07/2022 - 06/2013
8	Breast Neoplasms (Breast Cancer) 11/2020 - 05/2015
6	Inflammation (Inflammations) 12/2020 - 04/2014
5	Fatty Liver 01/2021 - 01/2018
4	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 06/2019
4	Fibrosis (Cirrhosis) 11/2019 - 01/2012
4	Coronary Disease (Coronary Heart Disease) 01/2017 - 05/2014
3	Insulin Resistance 01/2021 - 10/2019
3	Necrosis 01/2020 - 01/2019
3	Hypertriglyceridemia 01/2020 - 04/2015
3	Neoplasm Metastasis (Metastasis) 06/2019 - 01/2016
3	Carcinoma (Carcinomatosis) 01/2016 - 04/2014
3	Ureteral Obstruction 01/2013 - 01/2012
3	Hypoxia (Hypoxemia) 01/2013 - 01/2012
2	Adenocarcinoma of Lung 01/2022 - 01/2016
2	Carcinogenesis 09/2021 - 06/2013
2	Liver Cirrhosis (Hepatic Cirrhosis) 12/2020 - 11/2019
2	Body Weight (Weight, Body) 12/2020 - 06/2015
2	Non-alcoholic Fatty Liver Disease 12/2020 - 02/2018
2	Pituitary Neoplasms (Pituitary Adenoma) 04/2020 - 09/2019
2	Dyslipidemias (Dyslipidemia) 01/2020 - 04/2015
2	Cardiovascular Diseases (Cardiovascular Disease) 10/2019 - 01/2015
2	Diabetic Nephropathies (Diabetic Nephropathy) 10/2019 - 01/2018
2	Diabetic Retinopathy (Retinopathy, Diabetic) 06/2015 - 01/2015
1	Glioma (Gliomas) 07/2022
1	Obesity 01/2022
1	Ischemia 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 09/2021
1	Myalgia 01/2021
1	Pruritus (Itching) 01/2021
1	Fatigue 01/2021
1	Exanthema (Rash) 01/2021
1	Phototoxic Dermatitis (Phototoxicity) 01/2021
1	Heart Failure 12/2020
1	B-Cell Lymphoma (Lymphoma, B Cell) 12/2020

Drug/Important Bio-Agent (IBA)

12	Apolipoproteins E (ApoE)IBA 01/2021 - 04/2015
8	Liver X ReceptorsIBA 01/2021 - 12/2012
8	LigandsIBA 01/2021 - 12/2012
8	LipidsIBA 12/2020 - 06/2013
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2012
7	CholesterolIBA 01/2019 - 12/2012
6	T0901317IBA 01/2021 - 04/2014
6	naoxintongIBA 10/2019 - 01/2015
5	Capsules (Microcapsules)IBA 10/2019 - 01/2015
4	U 0126 (UO 126)IBA 01/2021 - 02/2015
4	Tamoxifen FDA LinkGeneric 11/2020 - 05/2015
4	Transcription Factors (Transcription Factor)IBA 10/2018 - 12/2012
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 01/2012
3	Biological ProductsIBA 07/2022 - 01/2018
3	Therapeutic UsesIBA 07/2022 - 01/2013
3	Small Interfering RNA (siRNA)IBA 01/2022 - 01/2012
3	CollagenIBA 11/2019 - 01/2012
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 02/2018 - 08/2015
3	ApolipoproteinsIBA 01/2018 - 05/2014
3	buchang naoxintongIBA 01/2017 - 01/2015
3	oxidized low density lipoproteinIBA 01/2016 - 12/2012
3	Fatty Acid-Binding ProteinsIBA 08/2015 - 06/2012
2	Circular RNAIBA 07/2022 - 01/2022
2	Long Noncoding RNAIBA 09/2021 - 01/2020
2	Triglycerides (Triacylglycerol)IBA 01/2021 - 01/2019
2	Transaminases (Aminotransferases)IBA 01/2021 - 01/2017
2	Alanine Transaminase (SGPT)IBA 01/2021 - 11/2019
2	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2020 - 01/2020
2	AdiponectinIBA 12/2020 - 01/2017
2	asparaginyl- isoleucyl- prolyl- norvalyl- leucyl- tyrosyl- seryl- phenylalanyl- alanyl- serinamideIBA 12/2020 - 01/2017
2	Glucose (Dextrose)FDA LinkGeneric 12/2020 - 06/2015
2	Adenosine Monophosphate (AMP)IBA 12/2020 - 02/2018
2	RNA (Ribonucleic Acid)IBA 11/2020 - 10/2018
2	Estrogen ReceptorsIBA 11/2020 - 12/2018
2	Growth Hormone (Somatotropin)IBA 04/2020 - 09/2019
2	Rosiglitazone (Avandia)FDA Link 01/2020 - 11/2019
2	InterferonsIBA 12/2018 - 02/2015
2	trioctyl phosphine oxide (TOPO)IBA 10/2018 - 06/2013
2	Teniposide (VM 26)FDA Link 10/2018 - 06/2013
2	danhongIBA 06/2015 - 05/2014
2	Etoposide (VP 16)FDA LinkGeneric 06/2015 - 06/2013
1	Sorafenib (BAY 43-9006)FDA Link 01/2022
1	Nanoparticle Drug Delivery SystemIBA 01/2022
1	HydrogelsIBA 01/2021
1	Blood Glucose (Blood Sugar)IBA 01/2021
1	Nonesterified Fatty Acids (NEFA)IBA 01/2021
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2021
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2021
1	Coordination ComplexesIBA 01/2021
1	Photosensitizing Agents (Photosensitizers)IBA 01/2021
1	Streptozocin (Streptozotocin)FDA Link 01/2021
1	PlatinumIBA 01/2021
1	Caspase 3 (Caspase-3)IBA 12/2020
1	Sirtuin 2IBA 12/2020
1	Peptides (Polypeptides)IBA 12/2020
1	bcl-2-Associated X Protein (bcl 2 Associated X Protein)IBA 12/2020

Therapy/Procedure

3	Therapeutics 01/2021 - 04/2015
3	Radiofrequency Ablation 01/2020 - 06/2019
2	Aftercare (After-Treatment) 01/2022 - 01/2017
1	Electrodes (Electrode) 01/2022
1	Subcutaneous Injections 01/2021
1	Photochemotherapy (Photodynamic Therapy) 01/2021
1	Drug Therapy (Chemotherapy) 01/2021
1	Oral Administration 01/2021